Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

by | Feb 4, 2026 | Stock Market

Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.

Article Attribution | Read More at Article Source